Search PubMed⌕ Search

Biomedical subjects

M Baccarani

Publications and source records attributed to M Baccarani.

At least 145 records · Page 8Linked to original sources
PubMed1992

Comparison of two methods for concentrating CD34+ cells from patients with acute non-lymphocytic leukemia.

The aim of the present study was to compare two different methods for obtaining CD34+ cells from the peripheral blood or the bone marrow of patients with acute non-lymphocytic leukemia (ANLL). Twenty-two samples, obtained from 19 patients, were density cut (Ficoll-Hypaque 1.077) and, after incubation with My10 antibody, separated by panning or by immunomagnetic beads. Immunomagnetic beads provided a significantly better separation than panning, either in terms of concentration of CD34+ cells (85.5 +/- 11.6% vs. 55.7 +/- 25.0%, p = 0.003) or in terms of depletion of CD34+ cells (3.9 +/- 8.0% vs. 30.9 +/- 26.3%, p = 0.008). This was consistent with the virtually complete depletion of colony forming cells (CFC) in the CD34 negative fraction and the recovery of virtually all the CFC in the positive fraction in the samples separated by immunomagnetic beads. In conclusion, separation by immunomagnetic beads can allow collection of nearly pure CD34+ and CD34- cell populations from patients with ANLL, thereby facilitating the study of the biological characteristics of these cell populations. Moreover the method is less time consuming than panning and is not toxic to the CFC.

Adolescent↗
PubMed1992

[CD34+ cells in the autotransplant of bone marrow and peripheral blood].

Identification of a glycoprotein expressed on 1.2% of normal bone marrow cells, including progenitors of all hematolymphopoietic lineages and pluripotent stem cells, has allowed the production of several monoclonal antibodies directed against the same structure and included in the new differentiation cluster CD34. Availability of these antibodies coupled with techniques of positive selection of normal progenitors has opened an interesting and new alternative for purging bone marrow. Two of these techniques (avidin-biotin immunoadsorption on column and paramagnetic microspheres) have found clinical application and recently data on the first series of patients transplanted with CD34+ cells enriched marrows have been published. In the area of peripheral blood stem cells transplantation, detection by flow cytometry of CD34+ cells in the peripheral blood should replace the poorly standardized CFU-GM assay, allowing the best timing of apheretic procedures and the easy quantification of stem cells number in a harvest. Combination of negative (tumor cell killing) and positive (hemopoietic stem cell purification) selection might result in a significant improvement of the purging procedure and in a larger application of autologous hematopoietic stem cell transplantation for hematological and non-hematological malignancies.

Antibodies, Monoclonal↗
PubMed1991

Granulocyte-macrophage colony-stimulating factor in acute non-lymphocytic leukemia before and after chemotherapy.

The introduction of hematopoietic growth factors into the management of leukemia can influence the outcome of treatment in several ways, depending on the sensitivity and the response of normal and leukemic cells. In this paper we report on the effects of the administration of Escherichia coli-produced, human recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) in 15 adult patients with acute nonlymphocytic leukemia (ANLL) resistant to first-line treatment or in relapse. GM-CSF was given at a dose of 5-10 micrograms/kg/day as a 6-h i.v. infusion, prior to chemotherapy (CHT) (for 7 days) and after CHT (until evidence of failure or of remission). In the pre-CHT period there was a clear trend towards an increase of circulating neutrophils (PMN) and/or blast cell count (median 0.3 vs. 1.0 x 10(9)/l for PMN, and 0.5 vs. 2.3 for blast cells). After chemotherapy, in the patients who achieved complete remission (CR), the median time to a PMN count greater than 0.5 x 10(9)/l and greater than 1 x 10(9)/l was 16 days (range 13-27) and 19 days (range 13-42) respectively. The outcome of treatment was CR for 8/15 (53%), death during induction for 3/15 (20%), and failure for 4/15 (27%). All failures occurred in patients with an increase of blast cell count during pre-CHT GM-CSF administration. Toxicity and side effects were minor, apart from an acute respiratory syndrome that developed twice in the same patient, at doses of 10 and 3 micrograms/kg/day. These data suggest that investigation of GM-CSF in the treatment of ANLL is worth pursuing, with special attention to GM-CSF effects prior to chemotherapy.

Adult↗
PubMed1991

[Multidrug resistance].

Explore the source record for details and available documents.

ATP Binding Cassette Transporter, Subfamily B, Mem↗
PubMed1989

Maintenance treatment of multiple myeloma.

In multiple myeloma (MM), low-cost maintenance treatment has some attractions, since maintenance of a small tumor is usually compatible with a fairly healthy state. However, the great majority of the studies of maintenance treatment have failed to show any clinical benefit. Based on simple theoretical consideration, it is shown that in MM response duration and survival are affected primarily by the residual tumor mass after primary treatment, and by the kinetics of the tumor. Continuation of maintenance treatment is likely to have a moderate effect. The main cause of that is identified in the presence or in the development of a substantial proportion of drug-resistant cells. Preliminary data suggest that only alpha-interferon can be useful for maintenance, and that it can act by slowing down the kinetics of the tumor.

Antineoplastic Agents↗
PubMed1989

[Therapy and iron supplements with ferritin iron during pregnancy. Randomized prospective study of 458 cases].

A randomized polycentric study was programmed to establish the effects of daily administration of ferritin iron from early pregnancy to puerperium. 254 women with normal iron balance at the beginning of their pregnancy were randomized receiving no supplements or 40 mg iron daily. At the end of pregnancy iron balance was still normal only in one third of the pregnant women of the first group versus two third of the second group. 204 women who were iron-deficient received daily 40 or 120 mg of iron; in this group anemia developed less frequently (13% versus 29%) and iron balance normalized in one subject on four; the great majority of these women remained iron-deficient. Unwanted effects of minimal or mild relevance, and almost always sporadic were observed in 6.5% of cases and with the reduction or withdraw of the treatment in only 1.4% of cases. These results showed that daily administration of ferritin iron during pregnancy is effective and well tolerated; furthermore they suggest that the treatment must be done with at least 60 mg daily in women with normal iron balance and protracted also after the puerperium in iron deficient subjects.

Anemia, Hypochromic↗